Startup profile · funding coverage
Rubi Laboratories funding, valuation and investors
Enzyme-based manufacturing of materials from carbon inputs.
Verified company research · funding, investors and latest developments
Keep track of Rubi Laboratories
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Undisclosed stage
$7.5M financing · March 17, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$7.5M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded
Investors in latest funding
Lead: AP Ventures , FH One Investments
Other: Talis Capital , CMPC Ventures , H&M Group , Understorey Ventures
Overview
Uses cell-free enzyme cascades to make cellulose and other industrial materials from carbon feedstocks. Its product areas include textiles, formulation ingredients and carbon-fiber precursors.
Why Rubi Laboratories is interesting
The company's offtake term sheets indicate commercial interest; they are not recognised revenue or evidence of delivered production.
Key facts
- AP Ventures portfolio classification: current, checked October 28, 2026. This is a manager-reported status, not an ownership percentage.
- Funding history covers the source-verified transactions recorded here; it is not a complete lifetime financing total.
Funding history (newest first)
Undisclosed stage
2026-03-17 $7.5M financing- AP Ventures (lead)
- FH One Investments (lead)
- Talis Capital (participant)
- CMPC Ventures (participant)
- H&M Group (participant)
- Understorey Ventures (participant)
Source: Read source · prnewswire.com
Investors in our directory
Funds linked from Rubi Laboratories's profile — open a fund page for stage focus and related deal articles.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Rubi Laboratories
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.